Efikasnost generičkog imatiniba u lečenju bolesnika sa hroničnom mijeloidnom leukemijom – rezultati jednog centra

  • Ivana Urošević Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Ivanka Perčić Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Marina Dragičević Jojkić Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Marina Dokić Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Amir El Farra Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Aleksandar Savić Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Ivana Milošević Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Nada Vlaisavljević Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Borivoj Sekulić Clinical Center Vojvodina, Clinic of Hemathology, Novi Sad, Serbia
  • Bela Balint Serbian Academy of Sciences and Arts, Department of Medical Sciences, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP190620095U
Ključne reči: leukemija, mijeloidna, hronična, imatinib mesilat, lekovi, generički, preživljavanje

Sažetak


Uvod/Cilj. Ciljna terapija je značajno izmenila uspeh lečenja bolesnika sa hroničnom mijeloidnom leukemijom (CML). Cilj rada je bio da se proceni efikasnost lečenja obolelih od CML generičkim imatinibom u našem centru. Metode. Istraživanje je bilo retrospektivno. Obuhvatilo je 101 obolelog od CML u hroničnj fazi. Bolesnici su bili podeljeni u dve grupe. Prvu grupu je činilo 55 bolesnika koji su inicijalno lečeni originalnim imatinibom i koji su kasnije tokom lečenja prevedeni na terapiju gneričkim imatinibom. Drugu grupu činilo je 46 novodijagnostikovanih bolesnika koji su od početka lečeni generičkim imatinibom. Rezultati. Bolesnici su originalnim imatinibom bili lečeni u proseku 42 meseca (od 6 do 132 meseca) nakon čega su prevedeni na generički imatinib. Lečenje generičkim imatinibom je u proseku trajalo 25 meseci (od 3 do 66 meseci). Četvrtina bolesnika prve grupe izgubila je citogenetski odgovor nakon prevođenja na generički imatinib. Nije bilo znakova za transformaciju u akutnu leukemiju. Bolesnici lečeni originalnim imatinibom imali su statistički značajno duže preživljavanje bez događaja koje podrazumeva smrtni ishod (event-free survival – EFS) i preživljavanje bez neuspeha terapije (failure-free survival – FFS) (log-rank p = 0,01 i p = 0,03, redom). Na ovakve rezultate mogla je da utiče učestala promena dozne formulacije i proizvođača generičkog imatiniba. Zaključak. Naše istraživanje ukazalo je na značajno duže EFS i FFS kod bolesnika koji su lečenje započeli originalnim imatinibom u odnosu na bolesnike koji su sve vreme lečeni generičkim imatinibom. Navedeni rezultati pružaju korisnu informaciju, ali se moraju tumačiti u kontekstu studije po tipu unakrsnog izajna. 

Reference

Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium - The just price. J Clin Oncol 2103; 31(28): 3600‒4.

Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011; 29(5): 524‒31.

O'Brien SG, Guilhot F, Larson RA, Gathmman I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994‒1004.

Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 2009; 114(22): 462. Abstract 1126.

Geissler J, Sharf G, Cugurovic J, Padua R, Narbutas S, Remic M, et al. Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer. Leukemia 2016; 30(12): 2396‒7.

Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Ap-perley JF. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122(6): 872‒84.

Goubran HA. Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J Med Case Rep 2009; 3: 7112.

Asfour IA, Elshazly SA. Changing therapy from Glivec to a ‘‘copy’’ imatinib results in a worsening of chronic myeloid leu-kemia disease status: two case reports. Cases J 2009; 2: 9342.

Chouffai Z. Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case Rep Oncol 2010; 3(2): 272–6.

Mattar M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leu-kemia in chronic phase. Int J Hematol 2010; 91(1): 104–6.

Razmkhah F, Razavi M, Zaker F, Kazemi A, Negari S, Rasighaemi P, et al. Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia. Lab Med 2010; 41(9): 547–50.

Nair V, Sharma A, Kotwal J, Bhishapathy M, Mishra DK, Das S, et al. Monitoring of responce to therapy with Imatinib mesyl-ate in chronic myeloid leukemia in chronic phase. Med J Armed Forces India 2014; 70(40): 315‒20.

Alwan AF, Matti BF, Naji AS, Muhammed AH, Abdulsahib MA. Prospective single center study of chronic myeloid leu-kemia in chronic phase: switching from branded Imatinib to a copy drug and back. Leuk Lymphoma 2014; 55(12): 2830‒4.

Eddou H, Astati S, Mahtat EM. The treatment of chronic mye-loid leukemia by Imatinib Mesylate generic: About 26 cases. 16th Congress of the European Hematology Association; Lon-don, UK; 2011 June 9‒12. Abstract Book (Abstract 1234.) Hematologica 2011; 96(Suppl 2): 1‒678.

Eskazan AE, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, et al. The efficacy of generic formulations of Imatinib Mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma 2014; 55(12): 2935‒7.

Malhotra H, Sharma R, Singh Y, Chaturvedi H. Report of chron-ic myeloid leukemia SMS Medical College Hospital, Jaipur. Indian J Med Paediatr Oncol 2013; 34(3): 177‒9.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362(24): 2251‒9.

Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs Imatinib in patients with newly diag-nosed Philadelphia chromosome-positive chronic myeloid leu-kemia in chronic phase. ENESTnd 3 year follow up. Leuke-mia 2012; 26(10): 2197‒203.

Islamagic E, Hasic A, Kurtovic S, Suljovic Hadzimesic E, Mehinovic L, Kozaric M, et al. The efficacy of generic imatinib as first- and second-line therapy: 3-year follow-up of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2017; 17: 238‒40.

Ostojic A, Sertic D, Roncevic P, Peric Z, Granic P, Matic N, et al. Comparison of branded and generic imatinib plasma concen-trations in patients with chronic myelogenous leukemia: uni-centric study. Clin Lymphoma Myeloma Leuk 2016; 16(8): 472‒6.

Objavljeno
2021/06/14
Broj časopisa
Vol. 78 Br. 5 (2021): Vojnosanitetski pregled
Rubrika
Originalni članak